Analysis

Filter
Clear Filter

FireEye (NSDQ: FEYE) dipped again on the news that Symantec (SYMC) is set to acquire Blue Coat Systems for $4.65 billion, effectively merging two of FireEye’s largest competitors. Despite the fact that Symantec has been lagging its younger rivals in developing technologies to detect more advanced threats, Blue Coat boasts… Read More

It’s summertime, and on Wall Street that usually means low volume days and sluggish price movements.  But Rollins (NYSE: ROL), a pest-control company, has a nifty ten-year record of summer gains.  The stock has rallied 80% of the time during the summer months since 2006.  A move above $29 could… Read More

Thank you for joining us on what we believe will be an epic journey. At the risk of sounding immodest, this inaugural issue of Breakthrough Tech Profits represents a new era in tech investing that will go far beyond the traditional boundaries of the information technology sector.Although a lot of… Read More

Last week Argos Therapeutics (ARGS) announced its COO was abruptly resigning and the company known for treating aggressive forms of cancer with immunotherapy would lay off 18 lab workers. The share price immediately plunged as a result, falling from more than $12 to below $8 in a matter of days.As… Read More

Last week Argos Therapeutics (ARGS) announced its COO was abruptly resigning and the company known for treating aggressive forms of cancer with immunotherapy would lay off 18 lab workers. The share price immediately plunged as a result, falling from more than $12 to below $8 in a matter of days.As… Read More

You’ve made a great decision to join me and my team for a year of explosive profits from traditional  technology companies as well as companies which leverage technology to solve some of the world’s biggest challenges.One such example is Argos Therapeutics which is already up 179% since we first recommended… Read More

Its no secret that embattled Yahoo (YHOO) CEO Marissa Mayer is under the gun to prove to shareholders that she should remain in her leadership position with the company. However, in this case its not only the CEO that is under the microscope, but the company’s entire board of directors… Read More

Special Situations Portfolio Update – Argos TherapeuticsFor those of you participating in our current cancer treatment play (“One Little Shot to Kill Cancer Dead“), tomorrow is an important day. One of the three stocks we recommend in that bundle – Argos Therapeutics (ARGS) – is releasing its fourth quarter… Read More

Long time subscribers to Smart Tech Investor may recall our story from last June on exoskeleton technology (“From Comic Books to Reality: Exoskeletons Are Here to Stay“), which recommended three companies that are currently held in our Special Situations Portfolio: Ekso Bionics (EKSO), ReWalk Robotics (RWLK) and Parker Hannifin (PH). Read More

All three of our Special Situations Portfolio "cancer stocks" - companies that are on the cutting edge of developing revolutionary treatment for some of the worst forms of cancer, were in the news recently. And almost all of the news was good, with all three stocks moving up smartly as a result. Read More